Solid Biosciences Inc. is a Strong Buy driven by positive FDA alignment on phase 3 IMPACT DUCHENNE trial for SGT-003. Read ...
The 2025-26 edition of the Champions League will be back next week when the 16 teams involved in the playoffs will take the ...
Solid Biosciences Inc (NASDAQ:SLDB) stock rose 3% in Monday’s premarket trading after the company announced positive regulatory developments for its Duchenne mu ...
Company aligned with FDA on Phase 3 randomized, double-blind, placebo-controlled trial design -- IMPACT DUCHENNE: Company ...
With a clutch of key data and planned regulatory applications this year from Avidity Biosciences, REGENXBIO and Capricor ...
Phase one of its upgrade plan covers seven southern Idaho counties. “We have about $36 million available to do infrastructure ...
GT Biopharma is set to begin a Phase I trial in mid-2026 of its B7-H3-targeting natural killer cell engager, after the US Food and Drug Administration cleared its investigational new drug application ...
Physicists have watched a quantum fluid do something once thought almost impossible: stop moving. In experiments with ...
Insilico Medicine announces the appointment of Dr. Halle Zhang, PhD (Med), as Vice President of Clinical Development – ...
The U.S.-based program between Karma and Factorial aims to move next-generation battery tech from the lab into real passenger ...
The trial is conducted at the Mays Cancer Center, part of the University of Texas at San Antonio’s Health Science Center.
Analysts parsed the limited data available for Pfizer’s obesity candidate on the pharma’s fourth-quarter earnings call Tuesday, looking for any nugget of additional context.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results